Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.
about
Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSATreatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.Can a routine follow-up blood culture be justified in Klebsiella pneumoniae bacteremia? A retrospective case-control studyCharacteristics of invasive Staphylococcus aureus infections in three regions of Korea, 2009-2011: a multi-center cohort studyActive surveillance of the trachea or throat for MRSA is more sensitive than nasal surveillance and a better predictor of MRSA infections among patients in intensive careClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.Clinical management of Staphylococcus aureus bacteremia: a review.Difference in agr dysfunction and reduced vancomycin susceptibility between MRSA bacteremia involving SCCmec types IV/IVa and I-III.The clinical characteristics, carbapenem resistance, and outcome of Acinetobacter bacteremia according to genospecies.Predictors of mortality in Staphylococcus aureus BacteremiaClinical update on linezolid in the treatment of Gram-positive bacterial infections.Fatal persistent methicillin-resistant Staphylococcus aureus bacteremia and vascular graft infections complicated with the formation of multiple abscesses despite aggressive medical therapy.Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.Persistent methicillin-resistant Staphylococcus aureus bacteremia: do we need a new therapeutic strategy?Identification, genotypic relation, and clinical features of colistin-resistant isolates of Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital.Outcome of intravenous azithromycin therapy in patients with complicated scrub typhus compared with that of doxycycline therapy using propensity-matched analysis.Rifampin combination therapy for nonmycobacterial infections.Invasive community-associated MRSA infections: epidemiology and antimicrobial management.MRSA: the first half century.Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence?Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy.Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice.When sepsis persists: a review of MRSA bacteraemia salvage therapy.Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection.Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the EurMultiple pathways of cross-resistance to glycopeptides and daptomycin in persistent MRSA bacteraemia.Methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections in solid organ transplantation.Vancomycin monotherapy vs. combination therapy for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia.The use of bone cement for the localized, controlled release of the antibiotics vancomycin, linezolid, or fusidic acid: effect of additives on drug release rates and mechanical strength.Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus.
P2860
Q22305769-A02D1A8D-D859-48AC-9EE5-C489DD64EAD7Q30449846-96588868-3AEA-4885-BD46-2689468913C3Q31125767-C1858A22-0724-4017-9E83-41F3D183D5B2Q33644439-3EC60DF5-88D9-4420-8949-EDDCB282CB5DQ33727368-FEF84029-799C-406C-86DF-F3711AC6FEF8Q34157657-2C8A14D1-5CA4-4782-8279-66D6C411CF45Q34290110-080B74D8-533D-434D-AF00-B123CBA02661Q34441035-969C1122-6289-4F8D-9E1E-EA03394FA9DEQ34477769-8C58312B-7FB4-4D3E-8D72-429BF6F66818Q34766027-227C3090-4AF9-4C49-9D4E-3710027B9308Q35940556-19C07CEB-C0DC-4F67-8339-EEADDC3CE763Q36083208-05CC219E-BF3E-4B65-AE3C-7436DE8DC8BCQ36871505-46C30FAB-7F16-4B2B-A4E2-1086100DF1E8Q37203845-0AF61389-AF99-4E8C-B947-7826975BCCC3Q37356494-F0BBA479-3B94-42D1-BD96-9289139CB134Q37643527-71F3A702-E12C-4F48-8E8B-F1325D1311A8Q37643690-EC71D4FD-A275-464B-BBB6-494F3689029CQ37672039-C709CB14-A5F1-43F1-8E6A-9CA10623F29DQ37800939-80FA1F34-F9D2-458A-B3F4-39D2A779BDEEQ37947249-DAD4CFD6-B190-4761-AA8E-7262F18C8F35Q38110140-9489D80D-4872-4ECD-9E11-339093F85FECQ38232494-1BEEDBCB-B2C4-44A9-8B75-C4B4EC105F95Q38462842-D16DF0EB-84AE-4CD3-A24C-CC6830781BA8Q38632488-91FD77D8-4653-40F2-98C8-95E3165B6CD6Q38843037-B48D8454-0EE1-4F7F-B5EE-02D5C5AED1AAQ39061989-699FEA31-C168-4538-A9A0-F57464D45B7FQ41026009-C34B9CD9-47AF-49E5-A2F9-9826566D5818Q41087225-EF4B2007-44A6-4246-A9B7-4757FA41A198Q42272352-B0CF401E-A52B-4AAA-9415-887256F72506Q42524512-46DC1E81-7172-4790-BCDA-35F307257220Q44046705-8EF4DE7E-18BC-4B46-9C3D-A6E921FE8E30Q47634145-6380ED60-CD3D-46BC-99A7-56A52A626C9CQ50723093-9F7421EC-81BA-489E-A7F7-1472ED9806A9
P2860
Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Salvage treatment for persiste ...... id with or without carbapenem.
@en
Salvage treatment for persiste ...... id with or without carbapenem.
@nl
type
label
Salvage treatment for persiste ...... id with or without carbapenem.
@en
Salvage treatment for persiste ...... id with or without carbapenem.
@nl
prefLabel
Salvage treatment for persiste ...... id with or without carbapenem.
@en
Salvage treatment for persiste ...... id with or without carbapenem.
@nl
P2093
P50
P356
P1476
Salvage treatment for persiste ...... id with or without carbapenem.
@en
P2093
Choong Jong Kim
Eui-Chong Kim
Jae Hyun Jeon
Kang Won Choe
Kye Hyoung Kim
Nam Joong Kim
Sang-Won Park
Sung-Han Kim
P304
P356
10.1086/600295
P407
P577
2009-08-01T00:00:00Z